Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
Curcumin induces cancer cell growth arrest and apoptosis in vitro, but its poor bioavailability in vivo limits its antitumor efficacy. We have previously evaluated the bioavailability of novel analogues of curcumin compared with curcumin, and we found that the analogue CDF exhibited greater systemic and pancreatic tissue bioavailability. In this study, we evaluated the effects of CDF or curcumin alone or in combination with gemcitabine on cell viability and apoptosis in gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer (PC) cell lines. Mechanistic investigations revealed a significant reduction in cell viability in CDF-treated cells compared with curcumin-treated cells, which were also associated with the induction of apoptosis, and these results were consistent with the downregulation of Akt, cyclooxygenase-2, prostaglandin E(2), vascular endothelial growth factor, and NF-kappaB DNA binding activity. We have also documented attenuated expression of miR-200 and increased expression of miR-21 (a signature of tumor aggressiveness) in gemcitabine-resistant cells relative to gemcitabine-sensitive cells. Interestingly, CDF treatment upregulated miR-200 expression and downregulated the expression of miR-21, and the downregulation of miR-21 resulted in the induction of PTEN. These results prompt further interest in CDF as a drug modality to improve treatment outcome of patients diagnosed with PC as a result of its greater bioavailability in pancreatic tissue.
Ali
Shadan
S
Division of Hematology/Oncology, Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA.
Ahmad
Aamir
A
Banerjee
Sanjeev
S
Padhye
Subhash
S
Dominiak
Kristin
K
Schaffert
Jacqueline M
JM
Wang
Zhiwei
Z
Philip
Philip A
PA
Sarkar
Fazlul H
FH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D003474:Curcumin / Q000008:administration & dosage / Q000494:pharmacology*; D018076:DNA, Complementary / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004357:Drug Synergism; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D020868:Gene Silencing; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000235:genetics; D051059:PTEN Phosphohydrolase / Q000235:genetics; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D014162:Transfection; D014315:Triterpenes / Q000008:administration & dosage / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism; D000093542:Gemcitabine
D018076:DNA, Complementary; D004273:DNA, Neoplasm; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D016328:NF-kappa B; D016376:Oligonucleotides, Antisense; D014315:Triterpenes; D042461:Vascular Endothelial Growth Factor A; C497962:cycloart-23Z-ene-3 beta,25-diol-3 beta-trans-ferulate; D003841:Deoxycytidine; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D003474:Curcumin; D015232:Dinoprostone; D000093542:Gemcitabine
Cancer Res. 2005 Aug 15;65(16):7065-70
16103053
Curr Genomics. 2008 Apr;9(2):97-109
19440450
Cancer Lett. 2008 Oct 8;269(2):199-225
18479807
Mol Cancer Ther. 2008 Mar;7(3):464-73
18347134
Gynecol Oncol. 2009 Sep;114(3):457-64
19501389
Cancer Res. 2008 Apr 1;68(7):2391-9
18381447
Cancer. 2004 Nov 15;101(10):2351-62
15476283
Mol Cancer Ther. 2004 Nov;3(11):1421-6
15542781
BMC Biotechnol. 2007 Jun 29;7:36
17603869
Int J Cancer. 2007 Mar 1;120(5):1046-54
17149698
Cancer Res. 2005 Jul 15;65(14):6029-33
16024602
Acta Biochim Biophys Sin (Shanghai). 2009 May;41(5):407-13
19430705
J Clin Oncol. 2009 Dec 1;27(34):5848-56
19884536
Pharm Res. 2009 Aug;26(8):1874-80
19421843
Pancreas. 2009 Oct;38(7):e190-9
19730150
Anticancer Res. 2006 Nov-Dec;26(6B):4423-30
17201164
Pharm Res. 2009 Nov;26(11):2438-45
19714451
Anticancer Agents Med Chem. 2009 Oct;9(8):904-12
19663790
Br J Cancer. 2009 May 5;100(9):1425-33
19401701
Mol Reprod Dev. 2009 Sep;76(9):854-62
19437447
Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51
18718806
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Cell Res. 2009 Jun;19(6):710-9
19365404
Mol Cancer Ther. 2005 Dec;4(12):1943-51
16373709
Cancer Res. 2007 Apr 15;67(8):3853-61
17440100
Mol Cancer Ther. 2008 Jun;7(6):1708-19
18566242
ScientificWorldJournal. 2008 Sep 21;8:901-4
18836656
Pancreas. 2008 Aug;37(2):121-7
18665070
Nutr Cancer. 2008;60 Suppl 1:81-9
19003584
Cancer Res. 2009 Aug 15;69(16):6704-12
19654291
Mol Pharm. 2007 Nov-Dec;4(6):807-18
17999464
Gastroenterology. 2007 Aug;133(2):647-58
17681183
Cancer Sci. 2009 Sep;100(9):1719-27
19558577
Cancer Res. 2006 Nov 1;66(21):10553-9
17079479
Cell Cycle. 2008 Oct;7(20):3112-8
18927505
JAMA. 2008 Jan 30;299(4):425-36
18230780
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S276-80
16507392
Bioorg Med Chem Lett. 2009 Apr 1;19(7):2065-9
19249204
Cancer Invest. 2007 Sep;25(6):411-8
17882652
Oncogene. 2003 May 22;22(21):3243-51
12761494
J Gastrointest Surg. 2008 Dec;12(12):2171-6
18642050
Gastroenterology. 2006 Jun;130(7):2113-29
16762633
Endocr Pathol. 2007 Fall;18(3):163-73
18058265
J Gastrointest Surg. 2008 Feb;12(2):288-96
18049840
Acta Pharmacol Toxicol (Copenh). 1978 Aug;43(2):86-92
696348
Oncogene. 2004 Nov 11;23(53):8571-80
15467756
Curr Drug Discov Technol. 2009 Sep;6(3):192-9
19496751